These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 19322080)

  • 1. Trials of cardiovascular risk factor management in type 2 diabetes.
    Patel A; Joshi R; de Galan B
    Curr Opin Cardiol; 2009 Jul; 24(4):288-94. PubMed ID: 19322080
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cardiovascular outcomes in type 2 diabetes: the impact of preventative therapies.
    Zoungas S; Patel A
    Ann N Y Acad Sci; 2010 Nov; 1212():29-40. PubMed ID: 21091713
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes.
    Tandon N; Ali MK; Narayan KM
    Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
    Fabbri G; Maggioni AP
    Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statins and diabetes.
    Carmena R; Betteridge DJ
    Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The best of epidemiology and cardiovascular prevention in 2006].
    Thomas D; Collet JP; Cottin Y; Cournot M; Ducimetière P; Ferrières J; Paillard F; Valensi P; Zeller M; Cambou JP
    Arch Mal Coeur Vaiss; 2007 Jan; 100 Spec No 1():57-64. PubMed ID: 17405566
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    J Am Coll Cardiol; 2004 Aug; 44(3):720-32. PubMed ID: 15358046
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Grundy SM; Cleeman JI; Merz CN; Brewer HB; Clark LT; Hunninghake DB; Pasternak RC; Smith SC; Stone NJ;
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):e149-61. PubMed ID: 15297292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reassessment of cardiovascular risk in diabetes.
    Jaffe JR; Nag SS; Landsman PB; Alexander CM
    Curr Opin Lipidol; 2006 Dec; 17(6):644-52. PubMed ID: 17095909
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.
    Cheng AY; Leiter LA
    Curr Opin Cardiol; 2006 Jul; 21(4):400-4. PubMed ID: 16755211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benefit of aspirin therapy in type 2 diabetes: what is the evidence?
    Sirois C; Poirier P; Moisan J; Grégoire JP
    Int J Cardiol; 2008 Sep; 129(2):172-9. PubMed ID: 18495263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcome studies in type 2 diabetes.
    Hanefeld M
    Curr Med Res Opin; 2005; 21 Suppl 1():S41-8. PubMed ID: 15811198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
    Fazio S
    Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving macrovascular outcomes in type 2 diabetes: Outcome studies in cardiovascular risk and metabolic control.
    Schneider CA
    Curr Med Res Opin; 2006; 22 Suppl 2():S15-26. PubMed ID: 16914072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
    Goff DC; Gerstein HC; Ginsberg HN; Cushman WC; Margolis KL; Byington RP; Buse JB; Genuth S; Probstfield JL; Simons-Morton DG;
    Am J Cardiol; 2007 Jun; 99(12A):4i-20i. PubMed ID: 17599424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid management with statins in type 2 diabetes mellitus.
    Irons BK; Kroon LA
    Ann Pharmacother; 2005 Oct; 39(10):1714-9. PubMed ID: 16118264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on aspirin in the treatment and prevention of cardiovascular disease.
    Hennekens CH
    Am J Manag Care; 2002 Dec; 8(22 Suppl):S691-700. PubMed ID: 12512736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Baseline characteristics of the Nateglinide and Valsartan Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) trial population: comparison with other diabetes prevention trials.
    Krum H; McMurray JJ; Horton E; Gerlock T; Holzhauer B; Zuurman L; Haffner SM; Bethel MA; Holman RR; Califf RM
    Cardiovasc Ther; 2010 Apr; 28(2):124-32. PubMed ID: 20184589
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.